VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
BIAFbioAffinity Technologies, Inc.
$0.83$4M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksBIAFRevenue History

BIAF logobioAffinity Technologies, Inc. (BIAF) Revenue History

Annual and quarterly revenue from 2019 to present

TTM Revenue$5.7M▼ $502K vs FY2025
YoY Growth-27.1%Declining
Q1 2026$1.4M-27.1% YoY · -15.1% QoQ
Revenue CAGR
3Y+986.6%
→
5Y—
→
10Y—
Best Fiscal Year$9.4M (2024)
Best Quarter$2.4M (Q1 2024)
Revenue per Share$1.25
Revenue per Employee$99K

BIAF Revenue Over Time (2019–2025)

BIAF Revenue Growth History

2 of 3 years with positive growth
Annual Revenue Growth · Each cell = one fiscal year
2019—
2020—
2021—
2022—
2023+52617.1%
2024+269.7%
2025-34.2%
FY2019 revenue growth
N/A
FY2020 revenue growth
N/A
FY2021 revenue growth
N/A
FY2022 revenue growth
N/A
FY2023 revenue growth
+52617.1%
FY2024 revenue growth
+269.7%
FY2025 revenue growth
-34.2%
DeclineStrong growth
↓ 1-year revenue declineBest: +52617.1% (FY2023)Worst: -34.2% (FY2025)
Recent Quarterly Revenue & YoY Growth
QuarterRevenueYoY
Q1 2026$1.4M-27.1%
Q4 2025$1.6M-27.8%
Q3 2025$1.4M-38.5%
Q2 2025$1.3M-47.1%
Q1 2025$1.9M-23.0%
Q4 2024$2.2M-0.3%
Q3 2024$2.4M+687.4%
Q2 2024$2.4M+12047.4%
Seasonal Revenue Pattern (fiscal quarters)
Q1
14%
Q2
19%
Q3
21%
Q4
46%

Multi-year avg. share of annual revenue by fiscal quarter

Revenue Breakdown (FY 2025)

BIAF's revenue distribution by segment and geography for fiscal year 2025

By Product/Segment

Health Care, Patient Service99.9%
Other Revenues0.1%

BIAF Revenue Analysis (2019–2025)

Current Revenue & Growth

As of June 23, 2026, bioAffinity Technologies, Inc. (BIAF) generated trailing twelve-month (TTM) revenue of $5.7 million, reflecting significant decline in growth of -27.1% year-over-year. The most recent quarter (Q1 2026) recorded $1.4 million in revenue, down 15.1% sequentially.

Historical Growth Trajectory

BIAF's historical revenue data shows a 3-year CAGR of +986.6%. bioAffinity Technologies, Inc.'s highest annual revenue of $9.4 million was recorded in 2024.

Revenue by Segment

BIAF's revenue is primarily driven by Health Care, Patient Service (100%), and Other Revenues (0%). With over half of revenue concentrated in Health Care, Patient Service, the company has a focused business model while developing other growth vectors.

Peer Comparison

Compared to Healthcare sector peers — including LUNG (+8.0% YoY), NVCR (+8.5% YoY), and CDNA (+19.2% YoY) — BIAF has underperformed the peer group in revenue growth. Compare BIAF vs LUNG →

BIAF Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
BIAF logoBIAFCurrent$6M-27.1%--171.6%
LUNG logoLUNG$90M+8.0%+22.6%-59.3%
NVCR logoNVCR$655M+8.5%+5.8%-23.5%
CDNA logoCDNA$380M+19.2%+14.6%-5.5%
EXAS logoEXAS$3.2B+17.7%+16.8%-6.4%
GKOS logoGKOS$507M+36.3%+17.7%-17.1%
Best in groupLowest in group

BIAF Historical Revenue Data (2019–2025)

1–7 of 7 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$6.2M-34.2%$1.4M23.2%$-10,572,508-171.6%
2024$9.4M+269.7%$3.4M36.1%$-8,953,000-95.6%
2023$2.5M+52617.1%$792K31.3%$-7,973,000-314.9%
2022$5K-$4K90.3%$-4,011,058-83511.5%
2021$0-$-4,817-$-2,206,822-
2020$0-$-22,242-$-2,604,385-
2019$0-$-40,278-$-3,092,242-
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

7+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

BIAF — Frequently Asked Questions

Quick answers to the most common questions about buying BIAF stock.

Is BIAF's revenue growth accelerating or slowing?

BIAF revenue is declining -27.1% year-over-year. TTM revenue fell to $6M, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.

What is BIAF's revenue history from 2019 to 2026?

bioAffinity Technologies, Inc. (BIAF) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $6M, growing at -27.1% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.

What is BIAF's long-term revenue growth rate (CAGR)?

bioAffinity Technologies, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -27.1% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for BIAF.

Why does BIAF's quarterly revenue fluctuate?

BIAF quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. bioAffinity Technologies, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.

How is BIAF's revenue distributed by segment?

BIAF reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.

How does BIAF's revenue compare to industry peers?

bioAffinity Technologies, Inc. (BIAF) with TTM revenue of $6M and -27.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.